ArticleViruses2009
Molecular mechanisms underlying hepatocellular carcinoma.
Article in Viruses, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Sex disparities in primary biliary cholangitis: insights from a Japanese multicentre cohort.Medical molecular morphology · 2026Article
- Construction and validation of gene signature for prognosis and drug sensitivity in cholangiocarcinoma based on cellular senescence related genes.Scientific reports · 2025Article
- Network pharmacological evaluation of strigolactones efficacy as potential inhibitors against therapeutic targets of hepatocellular carcinoma.Biotechnology letters · 2022Article
- Silencing of RND3/RHOE inhibits the growth of human hepatocellular carcinoma and is associated with reversible senescence.Cancer gene therapy · 2022Article
- The IGF-1 Signaling Pathway in Viral Infections.Viruses · 2021Review
- miR-221-3p promotes hepatocellular carcinogenesis by downregulating O6-methylguanine-DNA methyltransferase.Cancer biology & therapy · 2020Article
- Antiproliferative and Pro-Apoptotic Effect of Uvaol in Human Hepatocarcinoma HepG2 Cells by Affecting G0/G1 Cell Cycle Arrest, ROS Production and AKT/PI3K Signaling Pathway.Molecules (Basel, Switzerland) · 2020Article
- Review
- Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment.Cancers · 2019Review
- Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies.Medicina (Kaunas, Lithuania) · 2019Review
- Mechanisms of hepatocellular carcinoma progression.World journal of gastroenterology · 2019Review
- Current Research Progress on Long Noncoding RNAs Associated with Hepatocellular Carcinoma.Analytical cellular pathology (Amsterdam) · 2019Review
- Article
- Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells.International journal of molecular sciences · 2017Article
- WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues.Journal of cell communication and signaling · 2015Article
- Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation.World journal of hepatology · 2015Review
- Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law.Liver cancer · 2014Review
- Biochemical/metabolic changes associated with hepatocellular carcinoma development in mice.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Infectious agents and cancer · 2014Review
- Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.BMC cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocarcinogenesis is a complex process that remains still partly understood. That might be explained by the multiplicity of etiologic factors, the genetic/epigenetic heterogeneity of tumors bulks and the ignorance of the liver cell types that give rise to tumorigenic cells that have stem cell-like properties. The DNA stress induced by hepatocyte turnover, inflammation and maybe early oncogenic pathway activation and sometimes viral factors, leads to DNA damage response which activates the key tumor suppressive checkpoints p53/p21(Cip1) and p16(INK4a)/pRb responsible of cell cycle arrest and cellular senescence as reflected by the cirrhosis stage. Still obscure mechanisms, but maybe involving the Wnt signaling and Twist proteins, would allow pre-senescent hepatocytes to bypass senescence, acquire immortality by telomerase reactivation and get the last genetic/epigenetic hits necessary for cancerous transformation. Among some of the oncogenic pathways that might play key driving roles in hepatocarcinogenesis, c-myc and the Wnt/β-catenin signaling seem of particular interest. Finally, antiproliferative and apoptosis deficiencies involving TGF-β, Akt/PTEN, IGF2 pathways for instance are prerequisite for cancerous transformation. Of evidence, not only the transformed liver cell per se but the facilitating microenvironment is of fundamental importance for tumor bulk growth and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.